RT Journal Article SR Electronic T1 Sclerotherapy for Orbital Lymphangioma – Case Series and Literature Review JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 263 OP 266 VO 31 IS 2 A1 KARNESH CHANDRAKANT PATEL A1 GEORGE KALANTZIS A1 NABIL EL-HINDY A1 BERNARD Y. CHANG YR 2017 UL http://iv.iiarjournals.org/content/31/2/263.abstract AB Orbital lymphangioma is a lymphatic system lesion that commonly presents in childhood. Management of these lesions is complex. Sclerotherapy is a therapy used to treat and shrink lesions prior to or as an alternative to surgery. We present three cases of orbital lymphangioma that were treated with sclerotherapy. Case 1: A 6-month-old boy was presented in 2010 with right ptosis and proptosis. Magnetic resonance imaging (MRI) identified a lesion involving the right orbit and face. Case 2: A 3-year-old girl was presented in 2011 with intermittent right periorbital swelling and medial canthal bleeding. MRI identified a soft-tissue lesion in the right orbit, extending into the face. Case 3: A 3-year-old girl was presented in 2012 with vomiting, and painful right proptosis. MRI identified an intra-conal lesion in the right orbit with fluid filled levels. All three patients were treated with sclerotherapy (sodium tetradecylsulfate). Sclerotherapy is a promising treatment for orbital lymphangioma. Its use may prevent the need for, or minimise the amount of surgical management. Several sclerosants are now commonly used to treat these lesions.